Protalix Biotherapeutics (NYSEAMERICAN:PLX) announced its quarterly earnings data on Wednesday. The company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.06), RTT News reports. The company had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $8.00 million. During the same quarter in the previous year, the company earned ($0.09) earnings per share.
Protalix Biotherapeutics stock remained flat at $$0.46 during trading hours on Thursday. The company’s stock had a trading volume of 194,548 shares, compared to its average volume of 731,103. Protalix Biotherapeutics has a 12 month low of $0.38 and a 12 month high of $0.83.
A hedge fund recently raised its stake in Protalix Biotherapeutics stock. Renaissance Technologies LLC grew its stake in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 13.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,614,700 shares of the company’s stock after acquiring an additional 305,200 shares during the quarter. Renaissance Technologies LLC owned about 1.80% of Protalix Biotherapeutics worth $1,124,000 at the end of the most recent quarter.
About Protalix Biotherapeutics
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Further Reading: Discover Your Risk Tolerance
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.